Marisa Wexler, MS, senior science writer —

Anti-CD19 CAR T-cell therapy was found to be effective in treating a 54-year-old man with Lambert-Eaton myasthenic syndrome (LEMS) who wasn’t responding to other immune-suppressing and symptomatic treatments, according to a case report from researchers in Germany. The team’s observations suggest that this type of cell therapy may be…

Firdapse (amifampridine) can help ease symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in patients who don’t have an underlying cancer and its efficacy is consistent regardless of how long a delay there is before it’s started. That’s according to a study, “Safety, efficacy and steroid-sparing…

The rare case of a man with lung cancer complicated by two co-occurring cancer-associated syndromes — Lambert-Eaton myasthenic syndrome (LEMS) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) — was described in a recent report. According to its scientists, only four other documented reports of LEMS and SIADH developing…

DyDo Pharma is seeking approval of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in Japan. A decision from Japan’s Pharmaceuticals and Medical Devices Agency is expected in September. DyDo’s application was submitted in collaboration with Catalyst Pharmaceuticals, which developed Firdapse. DyDo is leading the development…

The rare case of a man with Lambert-Eaton myasthenia syndrome (LEMS) that co-occurred with non-Hodgkin lymphoma, a type of immune cell cancer, was described in a recent report. “In this case report, we present the case of a 57-year-old male diagnosed with non-Hodgkin’s lymphoma (NHL) who developed LEMS, an…

In the first documented case of its kind, spontaneous cancer regression was seen in a man in Japan with Lambert-Eaton myasthenic syndrome (LEMS) associated with lung cancer. Given that cancer-associated LEMS is thought to be triggered by the immune system attacking cancer cells, scientists believe such a LEMS-driving immune…

Lambert-Eaton myasthenic syndrome (LEMS) may be underdiagnosed in a sizeable fraction of people with small cell lung cancer (SCLC), a study analyzing real-world data suggests. Based on these findings, scientists argue that standardized protocols to screen people with SCLC for LEMS “may be warranted.” David Morrell, senior vice president…

Using digital tools to measure changes in gait and other aspects of physical activity outside of a hospital setting is a promising avenue for research in rare neurological disorders like Lambert-Eaton myasthenic syndrome (LEMS) — but more research is needed to validate these tools for use in studies. That’s…

Proposed policy changes that would let Medicare set prices for therapies earlier could result in fewer new medicines being approved over the next decade and rare diseases like Lambert-Eaton myasthenic syndrome (LEMS) may be among the most affected. That’s according to an analysis from Vital Transformation, whose clients…

Most adults in the general public in Japan support using public funds to help cover the costs of treatment for people with rare diseases, according to a recent study. The study, “General public’s understanding of rare diseases and their opinions on medical resource allocation in Japan: a…